Imagion Biosystems Ltd. · ASX:IBX
Imagion Biosystems — Investor Presentation (September 2026)
12 slides from Imagion Biosystems's investor presentation, Sep 4, 2026
Slide 1: Molecular MRI: The Next Generation of Imaging
B R E A K T H R O U G H F O R E A R LY C A N C E R D E T E C T I O N For personal use only Molecular MRI: The Next Generation of Imaging Imagion Biosystems Limited A SX : I BX Se pt emb er 2026
Slide 2: Forward Looking Statements
For wa rd L ooki n g St at e m e n t s This investor presentation (Presentation) has been prepared by Imagion Biosystems Limited (Imagion or the This presentation includes forward-looking statements that reflect Imagion's intentions, beliefs or current Company). This presentation does not constitute
Slide 3: Changing How We See Cancer
COMPANY OVERVIEW Changing How We See Cancer For personal use only • Clinical Stage Biotech in Phase 2 of clinical investigations • Highly Differentiated and first-of-its-kind for cancer detection • Next Generation Tech able to challenge the radiopharmaceutical market St ro ng Pi pel i ne Ad dressing
Slide 4: Current Diagnosis Takes Too Long
THE UNMET MEDICAL NEED Current Diagnosis Takes Too Long For personal use only Screening • Blood-based tests indicate risk but are non-diagnostic and require confirmation before treatment Conventional Imaging • Non-invasive but non-specific: cannot differentiate benign lesions from malignant tumors w
Slide 5: Earlier, More Accurate Cancer Detection
MOLECULAR MRI Earlier, More Accurate Cancer Detection For personal use only MagSense® imaging agents combined with MRI’s STANDARD MRI MagSense® MRI high resolution delivers clearer, more confident imaging to support earlier, more definitive diagnoses. MagSense particles are coated with unique target
Slide 6: MagSense Imaging Agents Can Be Applied to Many Types of Cancer
PLATFORM TECHNOLOGY – ADDITIONAL INDICATIONS MagSense® Imaging Agents Can Be Applied to Many Types of Cancer For personal use only Pre-Dose Post-Dose • All MagSense agents work the same, making the regulatory path clear and commercialization and adoption easier • Changing the MagSense targeting mole
Slide 7: The Phase 1 Trial in HER2 Positive Breast Cancer Met All Endpoints
CLINICAL DEVELOPMENT The Phase 1 Trial in HER2 Positive Breast Cancer Subjects Met All Endpoints 1 For personal use only • Phase 1 trial conducted in patients with HER2+ breast Baseline Post-MagSense® cancer (N=13) • Imaging agent was generally safe and well tolerated in all patients • Blinded revie
Slide 8: The Phase 2 HER2+ Clinical Trial IND Cleared by FDA
CLINICAL DEVELOPMENT The Phase 2 HER2+ Clinical Trial IND Key Near Term Activities: Cleared by For personal use only FDA • Contract 1st clinical site(s) after completing local institutional reviews • Activate site(s) after training on the study protocol and procedures • Open the trial for enrolment
Slide 9: The Next Generation of Molecular Imaging
The Next Generation of Molecular Imaging For personal use only RAD IO PHA RMACEU TICAL S & NON -RAD IO PHA RMAC EU TIC AL C ON T R A ST M E DI A M A RK ET L EA D ER S T H E R AN O ST IC S Contrast Enhanced MRI PET MagSense® mMRI ✓ Gadolinium-Based Contrast Agents ✓ High sensitivity ✓ No radioactivit
Slide 10: Investment Rationale
Investment Rationale LARGE MARKETS WITH AN UNMET MEDICAL NEED REDUCED TECHNICAL RISK For personal use only UPSIDE LEVERAGE • Global cancer incidence to rise • High rate of contrast media • Large ASX Peer Valuations, 77% by 2050 with screening & products achieve regulatory Potential for Strategic Par
Slide 11: Company Leadership
Company Leadership For personal use only Robert Proulx MAICD Melanie Leydin CA FGIA Nina Webster PhD, MBA, M.IP.Law Brett Mitchell Executive Chairman Co.Sec. and Non-Executive Director Non-Executive Director Non-Executive Director Robert is an operationally oriented executive with over Melanie is a
Slide 12: A Breakthrough for Early Cancer Detection
For personal use only • FIRST OF ITS KIND IN MOLECULAR MRI • NEXT GENERATION TECH TO DISRUPT RADIOPHARMACEUTICAL MARKET • MULTIPLE INDICATIONS IN DEVELOPMENT A BREAKTHROUH FOR • MULTI-BILLION DOLLAR MARKET E AR LY C AN CE R D ETE CTI O N OPPORTUNITY Imagion Biosystems Limited ASX: IBX i n f o @ i m
Imagion Biosystems — Investor Presentation (September 2026) on 6ix